Evidence map›Paper›PMID 38793074›Full record

ArticleJournal of personalized medicine2024

Liver Diseases: Science, Fiction and the Foreseeable Future.

Robert K Gieseler, Theodor Baars, Mustafa K Özçürümez, Ali Canbay

Abstract readEditorial
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert K GieselerDepartment of Medicine, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, 44892 Bochum, Germany.ORCID 0000-0002-3064-8516
Theodor BaarsDepartment of Medicine, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, 44892 Bochum, Germany.ORCID 0000-0002-1862-6461
Mustafa K ÖzçürümezDepartment of Medicine, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, 44892 Bochum, Germany.ORCID 0000-0002-4360-5005
Ali CanbayDepartment of Medicine, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, 44892 Bochum, Germany.ORCID 0000-0001-6069-7899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Editorial precedes the Special Issue entitled "Novel Challenges and Therapeutic Options for Liver Diseases". Following a historical outline of the roots of hepatology, we provide a brief insight into our colleagues' contributions in this issue on the current developments in this discipline related to the prevention of liver diseases, the metabolic dysfunction-associated steatotic liver disease (or non-alcoholic fatty liver disease, respectively), liver cirrhosis, chronic viral hepatitides, acute-on-chronic liver failure, liver transplantation, the liver-microbiome axis and microbiome transplantation, and telemedicine. We further add some topics not covered by the contributions herein that will likely impact future hepatology. Clinically, these comprise the predictive potential of organokine crosstalk and treatment options for liver fibrosis. With regard to promising developments in basic research, some current findings on the genetic basis of metabolism-associated chronic liver diseases, chronobiology, metabolic zonation of the liver, aspects of the aging liver against the background of demography, and liver regeneration will be presented. We expect machine learning to thrive as an overarching topic throughout hepatology. The largest study to date on the early detection of liver damage-which has been kicked off on 1 March 2024-is highlighted, too.

Indexed as

chronic viral hepatitideschronobiologyhistory of hepatologyliver agingliver fibrosis/cirrhosisliver–microbiome axisliver transplantationMASLD/NAFLDorganokine crosstalk

Identifiers

PMID38793074
PMCPMC11122384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.